Neural Network Cascade Optimizes MicroRNA Biomarker Selection for Nasopharyngeal Cancer Prognosis

MicroRNAs (miRNAs) have been shown to be promising biomarkers in predicting cancer prognosis. However, inappropriate or poorly optimized processing and modeling of miRNA expression data can negatively affect prediction performance. Here, we propose a holistic solution for miRNA biomarker selection and prediction model building. This work introduces the use of a neural network cascade, a cascaded constitution of small artificial neural network units, for evaluating miRNA expression and patient outcome. A miRNA microarray dataset of nasopharyngeal carcinoma was retrieved from Gene Expression Omnibus to illustrate the methodology. Results indicated a nonlinear relationship between miRNA expression and patient death risk, implying that direct comparison of expression values is inappropriate. However, this method performs transformation of miRNA expression values into a miRNA score, which linearly measures death risk. Spearman correlation was calculated between miRNA scores and survival status for each miRNA. Finally, a nine-miRNA signature was optimized to predict death risk after nasopharyngeal carcinoma by establishing a neural network cascade consisting of 13 artificial neural network units. Area under the ROC was 0.951 for the internal validation set and had a prediction accuracy of 83% for the external validation set. In particular, the established neural network cascade was found to have strong immunity against noise interference that disturbs miRNA expression values. This study provides an efficient and easy-to-use method that aims to maximize clinical application of miRNAs in prognostic risk assessment of patients with cancer.

[1]  Ji-Lin Wang,et al.  Candidate microRNA Biomarkers in Human Gastric Cancer: A Systematic Review and Validation Study , 2013, PloS one.

[2]  S. Kauppinen,et al.  Development of microRNA therapeutics is coming of age , 2014, EMBO molecular medicine.

[3]  Y. Toiyama,et al.  An update on microRNAs as colorectal cancer biomarkers: where are we and what’s next? , 2014, Expert review of molecular diagnostics.

[4]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[5]  Feng Jiang,et al.  MicroRNAs as potential biomarkers in human solid tumors. , 2013, Cancer letters.

[6]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[7]  Kurt Miller,et al.  Artificial neural networks and prostate cancer—tools for diagnosis and management , 2013, Nature Reviews Urology.

[8]  T. Boettger,et al.  A New Level of Complexity: The Role of MicroRNAs in Cardiovascular Development , 2012, Circulation research.

[9]  M. Tewari,et al.  MicroRNA profiling: approaches and considerations , 2012, Nature Reviews Genetics.

[10]  Zebo Huang,et al.  Prognostic Value of miR-21 in Various Cancers: An Updating Meta-Analysis , 2014, PloS one.

[11]  M. Rodicio,et al.  Analytical aspects of microRNA in diagnostics: a review. , 2011, Analytica chimica acta.

[12]  L. De Cecco,et al.  Measuring microRNA expression levels in oncology: from samples to data analysis. , 2013, Critical reviews in oncogenesis.

[13]  D. Linkens,et al.  Application of artificial intelligence to the management of urological cancer. , 2007, The Journal of urology.

[14]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[15]  R. Gregory,et al.  Many roads to maturity: microRNA biogenesis pathways and their regulation , 2009, Nature Cell Biology.

[16]  W. Cho MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. , 2010, The international journal of biochemistry & cell biology.

[17]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[18]  E. Gratacós,et al.  Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy , 2014, Scientific Reports.

[19]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[20]  D. M. Pereira,et al.  Delivering the promise of miRNA cancer therapeutics. , 2013, Drug discovery today.

[21]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[22]  Ying Sun,et al.  Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. , 2012, The Lancet. Oncology.

[23]  Paulo J. G. Lisboa,et al.  The Use of Artificial Neural Networks in Decision Support in Cancer: a Systematic Review , 2005 .

[24]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[25]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[26]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[27]  F. Slack,et al.  MicroRNAs as potential cancer therapeutics , 2008, Oncogene.